CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study